ï.	Picase type a plue sign)'' & \'.	App U.S. Palent and Trade TIS ATO required to respond to a confection of	PTO/SB/08A (08-00)
	Substitute for form 144	BAPTO SE	. 271		Complete If Known
I	111505144	12 ,	- ww 161	Application Number	10/602,214
	INFORMAT	ION DIS	CLOSURE	Filing Date	8/24/03
1	STATEMEN	T BY	PRINCANT	First Named Inventor	Quan et al.
ŀ				Group Art Unit	1624
-		iny sheets as	necessary) .	Exeminer Name	Unknown T. TRUENSE
1	Sheet 1	of	2 :	Attorney Docket Number	DM-6904 CNT 2

				U.S. PATENT DOCUM	ENTS	clas Isubclass	
Eventeer	0110	U.S. Petent Doc	ument	Name of Peterties or Applicant		1 / /	
Examiner initials	Cite No.1	Number Kind	Code ^s	, of Cited Dooument	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
TNI	1	5,202,330	Α	E. R. Squibb & Sons, Inc.	4/13/1993	514/274	
	/	5,317,103	Α	Merck Sharp & Dohrne Limited	5/31/1994	544/367	
	1/	5,342,851	Α	McNeil-PPC, Inc.	8/30/1994	574/370	
	0	5,463,071	Α	Dr. Karl Thomae GmbH	10/31/1995	548/287	
	/	5,616,601	A	GD Searle & Co	4/1/1997	514 /399	
	1	5,681,838	Α	Hoechst AG	10/28/1997	514 /307	
	1	5,707,998	A	; Eisai Co., Ltd.	1/13/1998	514/259	
	v,	6,020,357	Α	DuPont Pharma. : Company	2/1/2000	514/406	
TYV1	V					1	

		-		FOREIG	N PATENT DOCU	MENTS		
Examiner	Cite	For	eign Patent Do	oument i	Name of Patentee	Date of Publication of	Pagas, Columna, Lines,	
Initials*	No.1	Office ³	Number ⁴	Kind Code ⁶ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T _e
771	√	wo	9402477	Ą	Merck Sharp & Dohme Limited	2/3/1994	<u> </u>	
TMT	/	wo	9514683	Ą	DuPont Merck Pharma. Company	6/1/1995		
	1:	wo	9518111	A	DuPont Merck Pharma, Company	7/6/1995		
	<u>/</u>	wo	9628427	A	Berlex Lab., Inc.	9/19/1996		
	/	wo	9640143	A	SmithKline Beecham Corporation	12/19/1996		
	√ ·	wo	9723212	A _i	DuPont Merck Pharma. Company	7/3/1997		
MA		wo	9732583	A	SmithKline Beecham Corporation	9/12/1997		

Examiner Signature	Moni	Date	Florelox	_
		Considered	1/28/00	

EXAMINER: Initial if reference considered, whether or not cliction is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

[&]quot;Unique citation designation number." See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard 87.3). "For Japanese patent documents, the indication of the year of the reign of the Emporer must precede the serial number of the patent document." Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark hee if English language Translation is effected.

Please ty	pe e plus sign (+) insi Under the Pe		SIPE	persons	App. U.S. Petent and Trade nerequired to proport to a collection of	PTO/SB/08A (08-00) roved for use through 10/31/2002. OMB 0651-0091 mark Office: U.S. DEPARTMENT OF COMMERCE Information unless it contains a valid OMB control number.
Substitute	for form 1449A/PT	7	8	\		Compl te if Known
•	•		EP 1 2 2003 🗽	}	Application Number	10/602,214
INFO	RMATION	BIS	CLOSURE PRIJOS NT		Filing Date	6/24/03
STA	FEMENT B	YW	PPLICANT	•	First Named Inventor	Quan tal.
•			MADE		Group Art Unit	1624
	(use as many sh	eets as	nécessary)		Examiner Nama	Unknown TETRUONES
Sheet	2	of	2 ,		Attorney Docket Number	DM-6904 CNT 2

	•		FOREIG	N PATENT DOCU	MENTS		
	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines,	
No. ¹	Office ³	Number ⁴	Kind Code ⁸ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Vynere Kelevant Passages er Relevant Figures Appear	Te
V	EP	234830	A.	E. R. Squibb & Sons, Inc.	9/2/1987	<i>f</i>	
	EP	236902	Α	E. R. Squibb & Sons, Inc.	9/16/1987		
./	EP	513387	В	Otsuka Pharm. Co.	11/19/1992		
	E P	554829	A	Fujisawa Pharm. Co.	8/11/1993		,
	. JP	4247081	A	Takeda Chem. Ind. Ltd.	9/3/1992	Chemical Abstract	
			• •				
			+ + -				
		 	17				
	CHa No.1	Citie No. Office Deposition of the No. Office	Cite No.¹ Office³ Number⁴ EP 234830 EP 236902 EP 513387 EP 554829	Foreign Patent Document	Cite No. 1 Foreign Patent Document: Office Number Kind Code (If known) EP 234830 A E. R. Squibb & Sons, Inc. EP 236902 A Sons, Inc. EP 513387 B Otsuka Pharm. Co. EP 554829 A Fujisawa Pharm. Co. JP 4247081 A Takeda Chem. Ind. Ltd.	Cite No. 1 Office Number Kind Code (If known) or Applicant of Cited Document MM-DD-YYYY EP 234830 A E. R. Squibb & 9/2/1987 EP 236902 A E. R. Squibb & 9/16/1987 EP 513387 B Otsuka Pharm. Co. 11/19/1992 EP 554829 A Fujisawa Pharm. Co. 3/11/1993 JP 4247081 A Takeda Chem. Ind. Ltd. 9/3/1992	Cited Document Wind Codes of Applicant of Cited Document MM-DD-YYYY EP 234830 A E.R. Squibb & Sons, Inc. EP 236902 A Sons, Inc. EP 513387 B Otsuka Pharm. Co. EP 554829 A Fujisawa Pharm. Co. JP 4247081 A Takeda Chem. Ind. Ltd. Ind. Ltd. Name of Palentse of Application of Cited Document MM-DD-YYYY Passages or Relevant Passages or Relevant Figures Appear Where Relevant Passages or Relevant Figures Appear Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear Pages, Columns, Lines, Where Relevant Passages or Relevant Passages or Relevant Figures Appear Pages, Columns, Lines, Where Relevant Passages or Relevant P

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
TWI	1	TIDWELL et al. "Diarylamidine derivatives with one or both of the anyl moleties consisting of an indole- like ring. Inhibitors of arginine-specific esteroproteases". J. Med. Chem. (1978), 21(7), 613-623.	
		1	
		į.	
		é .	

		,	
Examiner		Date	7/20/
	// / '		1 7728105
Signature	10000	Considered	11000

'EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chef Information Officer, U.S. Patent and Tradamark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Unique cliation designation number. Applicant to to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this borpe

Approved for use through 10/31/2002, OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PT

Sheet

SEP 1 2 2003

INFORMATION DESCLOSUSE STATEMENT BY APPELLANT

(use as many sheets as necessary)

of 2

	Complete if Known	,
Application Number	10/602,214	_
Filing Date	6/24/03	_
First Named Inventor	Quan et al.	_
Group Art Unit		_
Examiner Name	Unknown	-
Attorney Docket Number	DM-6904 CN/f 2	_

				U.S. PATENT DOCUM	MENTS	/	
		U.S. Patent Doc.	ment	Name of Patentee or Applicant	Date of Publication at	Pages, Columns, Lines, Where Relevant	
Examiner Initials *	Cite No.1	Number Kind Code ² (if known)		of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
		5,202,330	Α	E, R. Squibb & Sons, Inc.	4/23/1993		
		5,317,103	Α	Merck Sharp & Dohme Limited	5/31/1994		
		5,342,851	Α	McNeil-PPC, Inc.	8/30/1994		
,		5,463,071	Α	Dr. Karl Thomae GmbH	10/31/1995		
,		5,616,601	Α	GD Searle & Co	4/1/1997		
		5,681,838	Α	Hoechst AG	10/28/1997		
	1.	5,707,998	Α	Eisai Co., Ltd.	1/13/1998		
		6,020,357	Α	DuPon Pharma. Company	2/1/2000		
•							

				50000				
	,	r .			N PATENT DOCU	MENTS		
Examiner Initials*	r Cite Foreign Patent Document Office³ Number⁴ Kind Code⁵ (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆		
		wo	9402477	Α	Merck Sharp & Dohme Limited	2/3/1994		
		·wo	9514683	А	DuPont Merck Pharma. Company	6/1/1995		
		wo	9518111	Α .	DuPont Merck Pharma. Company	7/6/1995		
		wo	9628427	А	Berlex Lab., Inc.	9/19/1996		
		wo	9640143	А	SmithKline Beecham Corporation	12/19/1996		,
		wo	9723212	. A	DuPont Merck Pharma. Company	7/3/1997		
	1.	wo	9732583	Α	SmithKline Beecham Corporation	9/12/1997		

Examiner Signature	Mon	Date Considered	7/28/05	
-----------------------	-----	--------------------	---------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁸ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Oul

.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCL STATEMENT BY

(use as many sheets as necessary)

Sheet 2 of

Complete If Known					
Application Number	10/602,214				
Filing Date	6/24/03				
First Named Inventor	Quan et al.				
Group Art Unit	1624				
Examiner Name	Unknown				
Attomore Docket Number	DM-6904 CNT 2				

				FOREIGI	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document		Name of Patentee	Date of Publication of	Pages, Columns, Lines,		
		Office ³	Number ⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ₆
		EP	234830	Α	E. R. Squibb & Sons, Inc.	9/2/1987		•
		EP	236902	Α	E. R. Squibb & Sons, Inc.	9/16/1987		
		EP	513387	В	Otsuka Pharm. Co.	11/19/1992		
/		EP	554829	Α	Fujisawa Pharm. Co.	8/11/1993		
		JP	4247081	Α	Takeda Chem. Ind. Ltd.	9/3/1992	Chemical Abstract	
		ļ		4	/			
<u> </u>		 	 					
		 	 	 -/-				
	L	<u> </u>						

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue					
		TIDWELL et al. "Diarylamidine derivatives with one or both of the aryl moleties consisting of an indole or indole-like ring inhibitors of arginine-specific esteroproteases". J. Med. Chem. (1978), 21(7), 613-623.				
,						
		·				

Examiner Signature	Mom	Date Considered	7/28/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case, Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.